Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

941. Costs and effectiveness of prostate cancer screening in elderly men

knowledge about prostate cancer, it may be reasonable for Medicare to consider reimbursement of the screening test. Reimbursement could be seen as ensuring that out-of-pocket screening expenses (however small) not impede well-informed discussion and decision-making between physician and patient. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Aged; Mass Screening; Medicare; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Radiation /therapy Language Published English (...) Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made

1995 Health Technology Assessment (HTA) Database.

942. Cost-effective prostate cancer detection: reduction of low-yield biopsies

1994; 74(12): 3146-3158 PubMedID Other publications of related interest Mettlin C J et al. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991;67:2949-58. Babaian R J et al. The relationship of PSA to DRE and TRUS in detecting adenocarcinoma of the prostate. Cancer 1992;69:1195-200. Kane R A et al. PSA levels in 1695 men without evidence of prostate cancer. Cancer 1992;69:1201-7. Mettlin C J et al. Characteristics of prostate cancers detected in multi-modality early (...) Cost-effective prostate cancer detection: reduction of low-yield biopsies Cost-effective prostate cancer detection: reduction of low-yield biopsies Cost-effective prostate cancer detection: reduction of low-yield biopsies Littrup P J, Kane R A, Mettlin C J, Murphy G P, Lee F, Toi A, Badalament R, Babaian R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results

1994 NHS Economic Evaluation Database.

943. Screening for prostate cancer: a decision analytic view

, incontinence), and long term outcomes associated with disease progression, including cancer mortality. Study designs and other criteria for inclusion in the review Studies published within the American Cancer Society National Prostate Cancer Detection Project were used to derive estimates of test sensitivity and specificity. Published case series were used to estimate treatment complications. To estimate disease progression and mortality rates, studies of any design were included(RCT, case series (...) Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Screening for prostate cancer: a decision analytic view Krahn M D, Mahoney J E, Eckman M H, Trachtenberg J, Pauker S G, Detsky A S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

1994 NHS Economic Evaluation Database.

944. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone

A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone McEwan A J, Amyotte G A, McGowan D G, MacGillivray J (...) A, Porter A T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of strontium isotope as adjunct therapy in patients with prostate cancer metastatic tothe bone. Type of intervention Palliative care. Economic study type Cost

1994 NHS Economic Evaluation Database.

945. Chest radiography in patients with early stage prostatic carcinoma: effect on treatment planning and cost analysis

Chest radiography in patients with early stage prostatic carcinoma: effect on treatment planning and cost analysis Chest radiography in patients with early stage prostatic carcinoma: effect on treatment planning and cost analysis Chest radiography in patients with early stage prostatic carcinoma: effect on treatment planning and cost analysis Forman H P, Fox L A, Glazer H S, McClennan B L, Anderson D C, Sage S S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Preoperative routine chest radiography in patients with early stage prostatic carcinoma. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Asymptomatic patients with prostatic carcinoma detected in a specific antigen

1994 NHS Economic Evaluation Database.

946. An economic rationale for prostate cancer screening

of the effectiveness data, where possible, could be useful. Implications of the study More research is necessary for the assessment of the mortality rates. Bibliographic details Benoit R M, Naslund M J. An economic rationale for prostate cancer screening. Urology 1994; 44(6): 795-803 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Breast Neoplasms /prevention & Cost-Benefit Analysis; Costs and Cost Analysis; Fee Schedules; Female; Humans; Male; Mass Screening /economics; Middle Aged; Prostatic (...) An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening Benoit R M, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health

1994 NHS Economic Evaluation Database.

947. Prostate-cancer surveillance: a cost-effective strategy

in stage A, B & C, keeping 'history and physical exam alone' as a relevant comparator. Source of funding None stated. Bibliographic details Schapira D V, Jarrett A R. Prostate-cancer surveillance: a cost-effective strategy. International Journal of Oncology 1993; 2(3): 473-477 Indexing Status Subject indexing assigned by CRD MeSH Bone Neoplasms /radionuclide imaging; Follow-Up Studies; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Predictive Value of Tests (...) Prostate-cancer surveillance: a cost-effective strategy Prostate-cancer surveillance: a cost-effective strategy Prostate-cancer surveillance: a cost-effective strategy Schapira D V, Jarrett A R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn

1993 NHS Economic Evaluation Database.

948. Prostatic cancer in the Nordic Countries

Prostatic cancer in the Nordic Countries Prostatic cancer in the Nordic Countries Prostatic cancer in the Nordic Countries Jonsson P M, Danneskiold-Samsoe B, Heggestad T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jonsson P M, Danneskiold-Samsoe B, Heggestad T. Prostatic cancer in the Nordic Countries. Danish Institute for Health (...) Services Research (DSI). 1992 Authors' objectives Study in variations in diagnosis and treatment of prostatic cancer in the Nordic countries. Authors' conclusions In spite of numerous scientific trails knowledge on prostatic cancer remains limited. The beneficial effects of screening are doubtful due to the lack of evidence that early detection may lead to prolongation of life or increased quality of life. Other output or dissemination activity: Impact not evaluated. Project page URL Indexing Status

1992 Health Technology Assessment (HTA) Database.

949. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. (Abstract)

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. The independent prognostic factors affecting survival were assessed in 240 men undergoing treatment for metastatic prostate cancer as part of a randomized clinical trial comparing the gonadotropin releasing hormone analogue Zoladex (goserelin acetate implant) with castration. In a multivariate analysis, the most highly significant predictors were the presence or absence of bone pain (...) less than 6.9 nmol/L, significant differences in survival were observed for patients with serum testosterone levels of 10.4 to 13.9, 13.9 to 17.3, and over 17.3 nmol/L. These results have important implications for the design and analysis of future clinical trials of hormone therapy and for counseling patients regarding the short-term prognosis of their disease.

1991 JAMA Controlled trial quality: uncertain

950. Costs and benefits of early detection of prostatic cancer

and the conclusions drawn. Health technology Rectal-digital examination for detecting prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Men, aged 50-69 years. Setting The study was carried out in Sweden. Dates to which data relate Price related to 1989. Source of effectiveness data Single study. Modelling Epidemiological cohort model (model of survival and disease). Measure of benefits used in the economic analysis Potentially curablecases detected (...) and benefits of early detection of prostatic cancer. Health Policy 1990; 16: 241-253 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Cost-Benefit Analysis; Decision Trees; Direct Service Costs; Humans; Male; Mass Screening /economics; Middle Aged; Neoplasms /prevention & Prostatic Neoplasms /prevention & Sweden; Ultrasonography /economics; control; control AccessionNumber 21995005185 Date bibliographic record published 27/06/1996 Date abstract record published 27/06/1996 NHS

1990 NHS Economic Evaluation Database.

951. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. (Abstract)

corrected for causes of death other than prostatic cancer was 93.8 (88.3-97.6)%. Univariate and multivariate analyses showed no association between age at diagnosis and the natural course. Local progression was less common in localised, non-palpable tumours than in larger tumours. The rate of progression was 18.7 (6.1-57.1) times higher and that of disease-specific death 216.0 (31.2-1496) times higher in patients with poorly than in those with highly differentiated tumours. It is concluded that tumour (...) Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. In a population-based study, disease progression and survival were evaluated in untreated patients with newly diagnosed cancer of the prostate without distant metastases. Complete follow-up was achieved in 223 of 227 (98%) consecutively diagnosed, eligible patients of all ages. After 5 years, the cumulative progression-free survival (with 95% confidence interval) was 71.8 (65.5-78.1)% and survival

1989 Lancet

952. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). (Abstract)

Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). Gonadotropin-releasing hormone (GnRH) analogues administered for the treatment of advanced prostatic cancer induce a transient increase in plasma testosterone levels during the first week of treatment, often with a secondary rise in plasma levels of prostatic acid phosphatase and a flareup of disease (...) . To determine whether the antiandrogen nilutamide (Anandron) blocks these effects, we carried out a multicenter, placebo-controlled study of nilutamide in men with prostatic cancer treated with the GnRH analogue buserelin. Thirty-six men with disseminated prostatic cancer and elevated plasma levels of prostatic acid phosphatase were randomly assigned to two groups. Group 1 included 17 men who received buserelin (500 micrograms daily subcutaneously) and nilutamide (300 mg daily by mouth); group 2 included 19

1989 NEJM Controlled trial quality: uncertain

953. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. (Abstract)

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. To test the hypothesis that maximal androgen blockade improves the effectiveness of the treatment of prostatic cancer, we conducted a randomized, double-blind trial in patients with disseminated, previously untreated prostate cancer (stage D2). All 603 men received leuprolide, an analogue of gonadotropin-releasing hormone that inhibits the release of gonadotropins, in combination with either placebo or flutamide (...) ; however, further studies should be conducted in this subgroup. Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade, when leuprolide alone often produces a painful flare in the disease. We conclude that in patients with advanced prostate cancer, treatment with leuprolide and flutamide is superior to treatment with leuprolide alone.

1989 NEJM Controlled trial quality: predicted high

954. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. (Abstract)

Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Safety and efficacy of a slow-release formulation of D-Trp-6-luteinising-hormone-releasing-hormone (D-Trp-6-LHRH) microcapsules were compared with orchidectomy in the initial treatment of advanced prostatic carcinoma. 41 patients were randomly assigned to D-Trp-6-LHRH and 38 to orchidectomy. Suppression of testosterone and reduction in prostatic acid phosphatase levels were (...) trend towards decreased psychological morbidity in the hormone group. The slow-release preparation of D-Trp-6-LHRH microcapsules offers an important alternative in the management of advanced prostatic carcinoma.

1985 Lancet Controlled trial quality: uncertain

955. A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination

A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination Love R R, Fryback D G, Kimbrough S R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for stage-B prostate cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Men, aged 60 years and over. Setting The study was carried out in the USA. Dates to which data relate Price related to 1984. Source of effectiveness data Review of studies. Modelling Epidemiological cohort model (model

1985 NHS Economic Evaluation Database.

956. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. (Abstract)

Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment. Initial therapy (leuprolide or DES) was continued for as long as an objective response was noted; cross-over (...) alternative treatment that is therapeutically equivalent to and causes fewer side effects than DES for the initial systemic management of metastatic prostate cancer.

1984 NEJM Controlled trial quality: uncertain